World Health Organization, 20, Avenue Appia, 1211 Geneva 27, Switzerland.
Vaccine. 2012 Mar 9;30(12):2212-9. doi: 10.1016/j.vaccine.2011.12.116. Epub 2012 Jan 24.
OBJECTIVE: Chronic hepatitis B virus infection is one of the most serious infections and a major risk factor for deaths from cirrhosis and liver cancer. We estimate age-, sex- and region-specific prevalence of chronic HBV infection and calculate the absolute number of persons being chronically infected. METHODS: A systematic review of the literature for studies reporting HBV infection was conducted and worldwide HBsAg seroprevalence data was collected over a 27-year period (1980-2007). Based on observed data, age-specific prevalence and endemicity were estimated on a global level and for all world regions for 1990 and 2005 using an empirical Bayesian hierarchical model. FINDINGS: From 1990 to 2005, the prevalence of chronic HBV infection decreased in most regions. This was particularly evident in Central sub-Saharan Africa, Tropical and Central Latin America, South East Asia and Central Europe. Despite this decrease in prevalence, the absolute number of HBsAg positive persons increased from 223 million in 1990 to 240 million in 2005. Age-specific prevalence varied by geographical region with highest endemicity levels in sub-Saharan Africa and prevalence below 2% in regions such as Tropical and Central Latin America, North America and Western Europe. Asian regions showed distinct prevalence patterns with lower intermediate prevalence in South Asia, but up to 8.6% HBsAg prevalence in East Asia. Strong declines were seen in South East Asian children. CONCLUSION: Declines in HBV infection prevalence may be related to expanded immunization. The increasing overall number of individuals being chronically infected with HBV, and the widespread global differences in HBV prevalence call for targeted approaches to tackle HBV-related mortality and morbidity. HBV infection prevalence data are needed at country and sub-national level to estimate disease burden and guide health and vaccine policy.
目的:慢性乙型肝炎病毒感染是最严重的感染之一,也是肝硬化和肝癌死亡的主要危险因素。我们估计了慢性乙型肝炎病毒感染在年龄、性别和地区的特定流行率,并计算了慢性感染的绝对人数。
方法:对报告乙型肝炎病毒感染的文献进行了系统回顾,并收集了 27 年来(1980-2007 年)全球 HBsAg 血清流行率数据。基于观察数据,使用经验贝叶斯层次模型,在全球和所有世界区域估计了 1990 年和 2005 年的年龄特异性流行率和地方性。
结果:从 1990 年到 2005 年,大多数地区慢性乙型肝炎病毒感染的流行率下降。这在撒哈拉以南非洲中部、热带和中拉丁美洲、东南亚和中欧尤为明显。尽管流行率下降,但 HBsAg 阳性者的绝对人数从 1990 年的 2.23 亿增加到 2005 年的 2.4 亿。年龄特异性流行率因地理区域而异,撒哈拉以南非洲的地方性水平最高,而热带和中拉丁美洲、北美和西欧等地区的流行率低于 2%。亚洲区域表现出明显的流行模式,南亚的中间流行率较低,但东亚的 HBsAg 流行率高达 8.6%。东南亚儿童的感染率明显下降。
结论:乙型肝炎病毒感染流行率的下降可能与免疫接种的扩大有关。感染乙型肝炎病毒的人数总体呈上升趋势,且乙型肝炎病毒的全球流行率存在广泛差异,这需要采取有针对性的方法来解决与乙型肝炎病毒相关的死亡率和发病率。需要在国家和次国家一级获得乙型肝炎病毒感染流行率数据,以评估疾病负担并指导卫生和疫苗政策。
J Gastrointestin Liver Dis. 2010-3
J Hepatol. 2016-8-31
Aust N Z J Public Health. 2004-6
Vaccine. 2010-8-17
Rwanda J Med Health Sci. 2023-11-30
Infect Dis Model. 2025-5-27
Front Oncol. 2025-5-16